Shares of Zydus Lifesciences fell more than 2% following the release of its Q2 financial results.
Quarter-over-Quarter (QoQ) Comparison
Revenue from Operations: ₹5,237 crore in Q2 FY25 vs ₹6,207.5 crore in Q1 FY25, a decline of 15.63%.
Net Profit: ₹911 crore in Q2 FY25 vs ₹1,419.9 crore in Q1 FY25, a decline of 35.83%.
Year-over-Year (YoY) Comparison
Revenue from Operations: ₹5,237 crore in Q2 FY25 vs ₹4,368.8 crore in Q2 FY24, an increase of 19.89%.
Net Profit: ₹911 crore in Q2 FY25 vs ₹801 crore in Q2 FY24, an increase of 13.7%.
As of 12:46 pm, Zydus Lifesciences shares were trading 1.90% lower at Rs 949.40 on the NSE.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
